open access

Vol 62, No 6 (2011)
Original papers
Published online: 2011-12-06
Submitted: 2013-02-15
Get Citation

Plasma levels of NT-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism

Dorota Pakuła, Bogdan Marek, Dariusz Kajdaniuk, Robert Krysiak, Beata Kos-Kudła, Piotr Pakuła, Aleksander Gatnar, Halina Borgiel-Marek, Mariusz Nowak, Lucyna Siemińska, Joanna Głogowska-Szeląg, Zofia Ostrowska
Endokrynologia Polska 2011;62(6):523-528.

open access

Vol 62, No 6 (2011)
Original papers
Published online: 2011-12-06
Submitted: 2013-02-15

Abstract

Background: Several studies have assessed natriuretic peptides in patients with thyroid disorders, and these studies have provided contrasting results. This difference may be partially explained by the presence of concomitant disorders of the cardiovascular system in participants.
Material and methods: The study included 101 patients free of any cardiovascular disorder, who, on the basis of plasma levels of TSH and thyroid hormones, were divided into patients with overt hyperthyroidism, patients with subclinical hyperthyroidism, patients with overt hypothyroidism, patients with subclinical hypothyroidism, and control subjects with normal thyroid profile. Hyperthyroidism was induced either by nodular thyroid disease or by Graves’ disease, while hypothyroidism was secondary to autoimmune thyroiditis or surgery.
Results: Compared to control subjects, hyperthyroid patients were characterised by higher plasma levels of NT-pro-BNP. This increase was particularly pronounced in cases of overt disease. On the other hand, neither clinical nor subclinical hypothyroidism was associated with any significant changes in this peptide. Plasma levels of NT-pro-BNP did not differ between patients with Graves’ disease and toxic nodular goitre nor between patients with autoimmune hypothyroidism and hypothyroidism secondary to thyroidectomy. Only L-thyroxine substitutions, but not hyperthyroidism treatment, caused changes in plasma concentration of NT-pro-BNP.
Conclusions: Hyperthyroidism and hypothyroidism induce changes of the plasma concentration of NT-pro-BNP. Although both exogenous L-thyroxine and antithyroid drugs restored thyroid function, only the former drug changed plasma NT-pro-BNP content. The thyrometabolic state of a patient should always be taken into consideration when NT-pro-BNP is assessed as a marker of cardiac dysfunction. (Pol J Endocrinol 2011; 62 (6): 523–528)

Abstract

Background: Several studies have assessed natriuretic peptides in patients with thyroid disorders, and these studies have provided contrasting results. This difference may be partially explained by the presence of concomitant disorders of the cardiovascular system in participants.
Material and methods: The study included 101 patients free of any cardiovascular disorder, who, on the basis of plasma levels of TSH and thyroid hormones, were divided into patients with overt hyperthyroidism, patients with subclinical hyperthyroidism, patients with overt hypothyroidism, patients with subclinical hypothyroidism, and control subjects with normal thyroid profile. Hyperthyroidism was induced either by nodular thyroid disease or by Graves’ disease, while hypothyroidism was secondary to autoimmune thyroiditis or surgery.
Results: Compared to control subjects, hyperthyroid patients were characterised by higher plasma levels of NT-pro-BNP. This increase was particularly pronounced in cases of overt disease. On the other hand, neither clinical nor subclinical hypothyroidism was associated with any significant changes in this peptide. Plasma levels of NT-pro-BNP did not differ between patients with Graves’ disease and toxic nodular goitre nor between patients with autoimmune hypothyroidism and hypothyroidism secondary to thyroidectomy. Only L-thyroxine substitutions, but not hyperthyroidism treatment, caused changes in plasma concentration of NT-pro-BNP.
Conclusions: Hyperthyroidism and hypothyroidism induce changes of the plasma concentration of NT-pro-BNP. Although both exogenous L-thyroxine and antithyroid drugs restored thyroid function, only the former drug changed plasma NT-pro-BNP content. The thyrometabolic state of a patient should always be taken into consideration when NT-pro-BNP is assessed as a marker of cardiac dysfunction. (Pol J Endocrinol 2011; 62 (6): 523–528)
Get Citation

Keywords

hyperthyroidism; hypothyroidism; L-thyroxine; brain natriuretic peptide; BNP; NT-pro-BNP

About this article
Title

Plasma levels of NT-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism

Journal

Endokrynologia Polska

Issue

Vol 62, No 6 (2011)

Pages

523-528

Published online

2011-12-06

Bibliographic record

Endokrynologia Polska 2011;62(6):523-528.

Keywords

hyperthyroidism
hypothyroidism
L-thyroxine
brain natriuretic peptide
BNP
NT-pro-BNP

Authors

Dorota Pakuła
Bogdan Marek
Dariusz Kajdaniuk
Robert Krysiak
Beata Kos-Kudła
Piotr Pakuła
Aleksander Gatnar
Halina Borgiel-Marek
Mariusz Nowak
Lucyna Siemińska
Joanna Głogowska-Szeląg
Zofia Ostrowska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl